Galmed Pharmaceuticals Ltd.

As of November 6, 2019, Galmed Pharmaceuticals Ltd. is considered overvalued with a valuation grade of "does not qualify," reflected by a Price to Book Value of 0.20, an EV to EBITDA of 2.05, a negative ROE of -36.74%, and a year-to-date stock performance of -45.14% compared to the S&P 500's 2.44%.

As of June 18, 2025, Galmed Pharmaceuticals Ltd. shows a mildly bullish trend supported by weekly MACD and KST indicators, despite some short-term bearish signals from daily moving averages and mixed signals from Bollinger Bands across different time frames.

As of March 2022, the management team of Galmed Pharmaceuticals Ltd. includes President and CEO Allen Baharaff, Lead Independent Director Dr. David Sidransky, Directors Marshall Heinberg and Prof. Ran Oren, and Independent Directors Dr. Carol Brosgart and William Marth. They oversee the company's strategic direction and operations.

Galmed Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing therapies for liver diseases, particularly Non-alcoholic Steatohepatitis (NASH), with its main product being Arachmol. As of March 2025, it has a market cap of USD 3.78 million and reported a net profit of -1 million.

As of Jun 18, Galmed Pharmaceuticals Ltd. has a market capitalization of 3.78 million and reported net sales of 0.00 million with a net profit of -7.34 million. Shareholder's funds are 16.33 million, and total assets are 18.50 million.